日报更新时间：
周报更新时间：01-16 11:49
今开价：
最高价：
成交量：
昨收价：
最低价：
最新价：
英文名称：Genocea Biosciences
简介：Genocea Biosciences, Inc.于2006年8月16日在特拉华州注册成立，它是一家处于临床阶段的生物制药公司，同时主要在马塞诸塞州的坎布里奇市开展业务
电话：1-617-8768191
Genocea Biosciences公司利用其专利发现平台Anigen Lead Acquisition System（ATLAS）来唤醒患者先前存在的CD4 +和CD8 + T细胞对肿瘤的免疫反应，鉴定抗原包含在旨在通过T细胞（或细胞）免疫应答起作用的疫苗中。Genocea Biosciences主要的免疫肿瘤学项目是GEN-009，一种佐剂化的新抗原肽疫苗候选物，处于临床前阶段，旨在指导患者的免疫系统攻击肿瘤。此外，Genocea Biosciences公司还寻求合作伙伴开发针对肿瘤相关抗原的癌症疫苗和针对由Epstein-Barr病毒引起的癌症的疫苗。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2017-07-23 | Poole Jonathan | Chief Financial Officer | Buy | 45000 | 3.09 |
| 2017-07-23 | Poole Jonathan | Chief Financial Officer | Sell | 45000 | 6.00 |
| 2017-05-18 | Siber (George R) | Director | Buy | 11230 | 2.38 |
| 2017-05-18 | Siber (George R) | Director | Buy | 11057 | 2.86 |
| 2017-05-18 | Siber (George R) | Director | Buy | 22287 | 6.07 |
| 2017-05-17 | Siber (George R) | Director | Buy | 31045 | 6.02 |
| 2017-05-17 | Siber (George R) | Director | Buy | 19281 | 2.38 |
| 2017-05-17 | Siber (George R) | Director | Buy | 10084 | 1.67 |
| 2017-05-17 | Siber (George R) | Director | Buy | 1680 | 2.38 |
| 2017-05-09 | Poole Jonathan | Chief Financial Officer | Sell | 3500 | 6.13 |
| 2017-05-07 | Poole Jonathan | Chief Financial Officer | Sell | 6213 | 6.51 |
| 2017-05-02 | Poole Jonathan | Chief Financial Officer | Buy | 7937 | -- |
| 2017-05-02 | Poole Jonathan | Chief Financial Officer | Buy | 23810 | -- |
| 2016-11-08 | Hetherington (Seth V) | Officer | Buy | 5000 | 2.02 |
| 2016-11-07 | Hoffman (Eric S) | Officer | Buy | 3000 | 3.59 |
| 2016-11-06 | Hoffman (Eric S) | Officer | Buy | 4000 | 3.41 |
| 2016-11-06 | Clark (William D) | Chief Executive Officer | Buy | 2800 | 3.49 |
| 2016-11-06 | Poole Jonathan | Chief Financial Officer | Buy | 7000 | 3.34 |
| 2016-05-08 | Poole Jonathan | Chief Financial Officer | Buy | 4000 | 3.88 |
| 2015-12-15 | Clark (William D) | Chief Executive Officer | Buy | 3800 | 6.45 |
| 2015-12-13 | Flechtner Jessica Baker | Officer | Buy | 5462 | 2.02 |
| 2015-12-13 | Flechtner Jessica Baker | Officer | Buy | 3444 | 2.02 |
| 2015-12-10 | Hetherington (Seth V) | Officer | Buy | 5000 | 2.02 |
| 2015-08-31 | Flechtner Jessica Baker | Officer | Sell | 2229 | 11.35 |
| 2015-08-31 | Flechtner Jessica Baker | Officer | Buy | 2229 | 2.02 |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Northern Trust Investments Inc | 22973 | 0.09% | -42100 | -64.70% | 2019-07-31 |
| BlackRock Fund Advisors | 3000474 | 1.44% | 25094 | 0.84% | 2019-07-31 |
| Polaris Venture Management Co. V,LLC | 1968606 | 1.75% | -- | -- | 2019-03-31 |
| Dafna Capital Management LLC | 1989653 | 1.77% | 1989653 | -- | 2019-03-31 |
| Ghost Tree Capital, LLC | 2000000 | 1.78% | -1525000 | -43.26% | 2019-03-31 |
| Vanguard Investments Australia Ltd | 477809 | 1.83% | 353879 | 285.55% | 2019-07-31 |
| Vivo Capital, LLC | 7811206 | 6.95% | -368794 | -4.51% | 2019-03-31 |
| Bvf Inc | 7828243 | 6.96% | 2713788 | 53.06% | 2019-03-31 |
| NEA Management Company, LLC | 34948269 | 31.09% | 9948269 | 39.79% | 2019-03-31 |
| Vanguard Group Inc | 1332451 | 1.19% | 29538 | 2.27% | 2019-03-31 |
| Apo Asset Management GmbH | 135853 | 0.52% | 90000 | 196.28% | 2019-07-31 |
| Fosun International Ltd | 571028 | 0.51% | 167350 | 41.46% | 2019-03-31 |
| Panagora Asset Management Inc | 117632 | 0.10% | 9683 | 8.97% | 2019-03-31 |
| Fidelity Management & Research Company | 27417 | 0.10% | -591607 | -95.57% | 2019-07-31 |
| Northern Trust Investments N A | 133717 | 0.12% | -- | -- | 2019-03-31 |
| Northern Trust Corp | 133717 | 0.12% | -- | -- | 2019-03-31 |
| Reichmuth & Co Integrale Vermogensverwaltung AG | 31690 | 0.12% | 21000 | 196.45% | 2019-07-31 |
| Hauck & Aufh | 403678 | 0.19% | -- | -- | 2019-07-31 |
| HighTower Advisors, LLC | 347100 | 0.31% | 230000 | 196.41% | 2019-03-31 |
| Renaissance Technologies Corp | 426254 | 0.38% | 213698 | 100.54% | 2019-03-31 |
| California Public Employees Retrmnt Sys | 60000 | 0.05% | -- | -- | 2019-03-31 |
| BlackRock Inc | 199040 | 0.18% | 1154 | 0.58% | 2018-12-31 |
| Geode Capital Management, LLC | 434688 | 0.39% | 217344 | 100.00% | 2018-12-31 |
| DRW Securities, LLC | 800911 | 0.71% | 331568 | 70.65% | 2018-12-31 |
| Birchview Capital, LP | 189000 | 0.17% | -- | -- | 2018-09-30 |
| Millennium Management LLC | 567989 | 0.66% | -285396 | -33.44% | 2018-09-30 |
| AXA Investment Managers UK Ltd | 571818 | 0.66% | -- | -- | 2018-12-31 |
| Franklin Advisers, Inc. | 1728000 | 1.99% | -1133200 | -39.61% | 2018-11-30 |
| Tekla Capital Management LLC | 3466666 | 4.00% | -- | -- | 2018-11-30 |
| Alyeska Investment Group, L.P. | 1603085 | 1.85% | -231719 | -12.63% | 2018-06-30 |
| Sunrise Partners LLC | 400899 | 0.46% | 400899 | -- | 2018-06-30 |
| Morgan Stanley - Brokerage Accounts | 300349 | 0.35% | 118101 | 64.80% | 2018-06-30 |
| Morgan Stanley & Co Inc | 300349 | 0.35% | 118101 | 64.80% | 2018-06-30 |
| BlueCrest Capital Management Ltd. | 285662 | 0.33% | 285662 | -- | 2018-06-30 |
| Fidelity Management and Research Company | 427323 | 0.49% | 1800 | 0.42% | 2018-03-31 |
| FMR Inc | 484523 | 0.56% | 1800 | 0.37% | 2018-03-31 |
| BlackRock Institutional Trust Company NA | 188084 | -- | -758296 | -80.13% | 2018-06-30 |
| LMR Partners LLP | 204774 | -- | 204774 | -- | 2018-06-30 |
| Element Capital Management LLC | 233776 | -- | 233776 | -- | 2018-06-30 |
| Medical Strategy GmbH | 323678 | -- | 323678 | -- | 2018-06-30 |
| Vivo Opportunity, LLC | 8180000 | -- | 8180000 | -- | 2018-01-17 |
| New Enterprise Associates 16, LP | 25000000 | -- | 25000000 | -- | 2018-01-17 |
| Quinn Opportunity Partners LLC | 113100 | -- | -- | -- | 2018-03-31 |
| Balyasny Asset Management LLC | 138088 | -- | -80596 | -36.86% | 2018-03-31 |
| Deutsche Bank AG | 214830 | -- | 154149 | 254.03% | 2018-03-31 |
| TIAA-CREF Investment Management LLC | 263874 | -- | 159800 | 153.54% | 2018-03-31 |
| GSA Capital Partners LLP | 234065 | -- | 170265 | 266.87% | 2018-03-31 |
| State Street Corp | 632135 | -- | 261200 | 70.42% | 2018-03-31 |
| Vassalluzzo Scott J | 185636 | -- | 13500 | 7.84% | 2018-03-31 |
| NorthPointe Capital LLC | 786634 | -- | -36943 | -4.49% | 2017-12-31 |
| Alphamark Advisors, LLC | 291934 | -- | -12952 | -4.25% | 2017-12-31 |
| Northern Trust Asset Management | 173412 | -- | -1154 | -0.66% | 2018-04-30 |
| BNY Mellon Investment Management | 72413 | -- | -327 | -0.45% | 2017-12-31 |
| Principal Life Insurance Co | 116250 | -- | 22632 | 24.17% | 2016-12-31 |
| Virtu Financial LLC | 202900 | -- | 202900 | -- | 2017-09-30 |
| Sphera Funds Management Ltd. | 490000 | -- | -- | -- | 2017-09-30 |
| AllianceBernstein LP | 578192 | -- | -7874 | -1.34% | 2017-09-30 |
| Bridgeway Capital Management, Inc | 151000 | -- | -- | -- | 2017-09-30 |
| IPConcept (Luxemburg) SA | 63953 | -- | 13953 | 27.91% | 2017-03-31 |
| Franklin Advisers Inc | 2994200 | 10.46% | -- | -- | 2017-06-30 |
| Principal Global Investors, LLC | 218100 | 0.76% | -- | -- | 2017-06-30 |
| T. Rowe Price Associates, Inc. | 35889 | 0.13% | 12030 | 50.42% | 2017-06-30 |
| Johnson & Johnson | 1330305 | 4.73% | -101215 | -7.07% | 2015-12-31 |
| Cvf LLC | 1226320 | 4.36% | 7580 | 0.62% | 2015-12-31 |
| Deerfield Management Co | 687257 | 2.42% | -- | -- | 2016-09-30 |
| Rock Springs Capital Management LP | 480000 | 1.69% | -- | -- | 2016-09-30 |
| CVF, LLC | 1218740 | 3.00% | 14454256 | -- | 1999-11-30 |
| Johnson Johnson Development Corporation | 1431520 | 3.00% | 16977827 | 0.10% | 1999-11-30 |
| S.R. One, Limited | 1971668 | 3.00% | 23383982 | 0.10% | 1999-11-30 |
| Stephen Hoffman, M.D., Ph.D. | 1992415 | 3.00% | 23630042 | 0.10% | 1999-11-30 |
| Kevin Bitterman, Ph.D. | 2055230 | 3.00% | 24375028 | 0.10% | 1999-11-30 |
| FMR LLC, and related funds | 3371523 | 3.00% | 39986263 | 0.10% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| MEDICAL BioHealth | 403678 | 0.19% | -- | -- | 2019-01-31 |
| NT US Market Cap Index Fund - Lending | 1354 | 0.01% | -- | -- | 2019-06-30 |
| Vanguard Total Stock Market Index Fund | 477809 | 1.83% | 353879 | 285.55% | 2019-06-30 |
| Vanguard Extended Market Index Fund | 243451 | 0.93% | 149517 | 159.17% | 2019-06-30 |
| APO Medical Opportunities | 111646 | 0.43% | 76000 | 213.21% | 2019-06-30 |
| RIM Global Bioscience | 31690 | 0.12% | 21000 | 196.45% | 2019-06-30 |
| apo Medical Opportunities Institutionell | 24207 | 0.09% | 14000 | 137.16% | 2019-06-30 |
| Vanguard Balanced Index Fund | 14841 | 0.06% | 10601 | 250.02% | 2019-06-30 |
| Vanguard Instl Total Stock Market Idx Fd | 13041 | 0.05% | -- | -- | 2019-06-30 |
| NT Extended Equity Market Idx Fund - NL | 8382 | 0.03% | -- | -- | 2019-06-30 |
| NT Ext Equity Market Index Fund - L | 6939 | 0.03% | -- | -- | 2019-06-30 |
| The Vanguard Total Stock Market Index | 2235 | 0.01% | 2235 | -- | 2019-06-30 |
| BNYM Mellon NSL Mkt Completion Fd Instl | 2451 | 0.01% | -- | -- | 2019-06-30 |
| State Street U.S. Extended Market Index | 2512 | 0.01% | -- | -- | 2019-06-30 |
| iShares Core S&P Total US Stock Mkt ETF | 1549 | 0.01% | -- | -- | 2019-07-30 |
| Fidelity | 2597 | 0.01% | 2597 | -- | 2019-06-30 |
| BlackRock Extended Equity Market | 4558 | 0.02% | -7 | -0.15% | 2019-06-30 |
| NT Ext Equity Mkt Fd - DC - NL | 5998 | 0.02% | 436 | 7.84% | 2019-06-30 |
| NT Ext Equity Mkt Idx Fd - DC - NL | 5998 | 0.02% | 436 | 7.84% | 2019-06-30 |
| BNYM Mellon SL Mkt Completion Fd | 5752 | 0.01% | -14496 | -71.59% | 2019-03-31 |
| Wells Fargo/SSGA Global Equity Index | 5724 | 0.01% | -- | -- | 2019-03-31 |
| iShares Core S&P US Total Market ETF | 1547 | 0.01% | -- | -- | 2019-05-30 |
| iShares Core Growth ETF Portfolio | 1548 | 0.01% | 1 | 0.06% | 2019-05-23 |
| iShares Core MSCI AllCntry Wld exCan ETF | 1548 | 0.01% | -- | -- | 2019-05-23 |
| iShares Core Balanced ETF Portfolio | 1548 | 0.01% | 1 | 0.06% | 2019-05-23 |
| BNYM Mellon NSL Market Completion Fund | 19608 | 0.02% | 18608 | 1860.80% | 2019-03-31 |
| PHARMA/wHEALTH | 32936 | 0.03% | -- | -- | 2018-07-31 |
| BNYM Mellon SL Market Completion Fund | 5752 | 0.01% | -14496 | -71.59% | 2019-03-31 |
| USAA Extended Market Index Fund | 3917 | -- | -- | -- | 2019-02-28 |
| NT Quality SCC US Fund - Non-Lending | 158 | -- | -- | -- | 2018-12-31 |
| NT Quality SCC Global Fund - Non-Lending | 158 | -- | -- | -- | 2018-12-31 |
| State Street Small/Mid Cap Eq Idx Port | -- | -- | -9900 | -100.00% | 2018-06-30 |
| SAST SA Small Cap Index Portfolio | -- | -- | -6028 | -100.00% | 2018-06-30 |
| BNY Mellon Market Completion Fund | 1000 | -- | -5390 | -84.35% | 2018-12-31 |
| iShares Russell 2000 Growth ETF | 684380 | 0.61% | 1180 | 0.17% | 2018-06-21 |
| iShares Micro-Cap ETF | 222657 | 0.20% | -- | -- | 2018-06-21 |
| iShares Russell 2000 Value ETF | 127055 | 0.11% | -210 | -0.17% | 2018-06-21 |
| X Russell 2000 ETF | 25663 | 0.02% | -2 | -0.01% | 2018-06-22 |
| iShares Russell 3000 ETF | 15821 | 0.01% | -- | -- | 2018-06-21 |
| Invesco Russell 2000 Equal Weight ETF | 7105 | 0.01% | 592 | 9.09% | 2018-06-24 |
| Invesco Wilshire Micro-Cap ETF | 11391 | 0.01% | -- | -- | 2019-01-31 |
| FCP MEDICAL BioHealth-Trends | 403678 | 0.47% | -- | -- | 2018-10-31 |
| RIM Global CC Bioscience | 26780 | 0.03% | -- | -- | 2018-11-30 |
| AXA 2000 Managed Volatility Portfolio | 116872 | 0.13% | -- | -- | 2018-05-31 |
| Vanguard Russell 2000 Index Fund | 85562 | 0.10% | 1331 | 1.58% | 2018-05-31 |
| Fidelity Advisor | 64200 | 0.07% | -- | -- | 2018-03-31 |
| iShares Russell 2000 Small-Cap Index Fd | 52290 | 0.06% | -- | -- | 2018-05-31 |
| VALIC Company I Small Cap Index Fund | 45712 | 0.05% | -- | -- | 2018-05-31 |
| TIAA-CREF Small-Cap Blend | 33811 | 0.04% | -- | -- | 2018-05-31 |
| Pacific Select Fund Small-Cap Index | 30909 | 0.04% | -- | -- | 2018-05-31 |
| Schwab Small Cap Index Fund | 168200 | 0.19% | -- | -- | 2018-05-31 |
| Franklin Biotechnology Discovery Fund | 1728000 | 1.99% | -- | -- | 2017-08-31 |
| Tekla World Healthcare Fund | 1333333 | 1.54% | -- | -- | 2017-12-31 |
| OMI IM GBP AXA Framlington Biotech | 571818 | 0.66% | -- | -- | 2017-09-30 |
| FCP MEDICAL BioHealth | 323678 | 0.37% | 323678 | -- | 2018-06-30 |
| AlphaMark Actively Managed Small Cap ETF | 272013 | 0.31% | -- | -- | 2018-01-17 |
| Strategic Advisers | 160000 | 0.18% | 160000 | -- | 2017-07-31 |
| TEKLA HEALTHCARE OPPORTUNITIES FUND | 2133333 | 2.46% | -- | -- | 2017-12-31 |
| Vanguard Instl Ttl Stk Mkt Idx InstlPls | 129073 | 0.15% | -- | -- | 2018-07-31 |
| Vanguard Russell 2000 Growth ETF | 84 | -- | -- | -- | 2018-07-31 |
| The Vanguard Russell 2000 Growth Index | 157 | -- | -- | -- | 2018-07-31 |
| Vanguard Total Stock Mkt Idx | 1225285 | 1.41% | -- | -- | 2018-07-31 |
| Vanguard Extended Market Idx Inv | 751470 | 0.87% | -- | -- | 2018-07-31 |
| State Street Russell Small/Mid Cap Idx Fd Cl I | 69972 | 0.24% | 69972 | -- | 2017-06-30 |
| Fidelity Spartan | 59471 | 0.07% | -- | -- | 2018-07-31 |
| BlackRock Extended Equity Market K | 36218 | 0.04% | 985 | 2.80% | 2018-06-30 |
| BNY Mellon EB DL Mkt Completion | 19853 | 0.02% | -- | -- | 2018-06-30 |
| Meeder Spectrum | 17406 | 0.02% | -- | -- | 2018-08-31 |
| Wilshire Micro-Cap ETF | 13751 | 0.01% | -- | -- | 2018-09-14 |
| BNY Mellon Market Completion Fund UC1 | 6390 | 0.01% | 5377 | 530.80% | 2018-03-31 |
| ProFunds Small Cap Inv | 459 | -- | -- | -- | 2018-04-30 |
| ProFunds UltraSmall Cap Inv | 1206 | -- | -126 | -9.46% | 2018-04-30 |
| USAA Extended Market Index | 3917 | -- | -- | -- | 2018-07-31 |
| Vanguard Balanced Index Inv | 7681 | 0.01% | -- | -- | 2018-07-31 |
| iShares Core S&P Total US Stock Mkt | 9708 | 0.01% | -- | -- | 2018-09-12 |
| SSgA U.S. Total Market Index Fd Class I | 5609 | 0.02% | -366 | -6.13% | 2017-12-31 |
| ProFunds VP UltraSmall-Cap | 333 | -- | -- | -- | 2018-03-31 |
| Consulting Group Small-Mid Cap Equity | 1818 | -- | -- | -- | 2018-05-31 |
| Bridge Builder Small/Mid Cap Growth | 20263 | 0.02% | 14282 | 238.79% | 2018-03-31 |
| State Farm Small Cap Index A Legacy | 19055 | 0.02% | 11790 | 162.28% | 2018-03-31 |
| State Farm VPT Small Cap Equity Index | 12171 | 0.01% | 7584 | 165.34% | 2018-03-31 |
| TIAA-CREF Equity Index Instl | 15937 | 0.02% | -- | -- | 2018-05-31 |
| CREF Equity Index R1 | 20661 | 0.02% | -- | -- | 2018-05-31 |
| TIAA-CREF Small-Cap Blend Idx Inst | 33811 | 0.04% | -- | -- | 2018-05-31 |
| VALIC Company I Small Cap Index | 45712 | 0.05% | -- | -- | 2018-05-31 |
| CREF Stock R1 | 243213 | 0.29% | -- | -- | 2018-04-30 |
| LVIP SSgA Small Cap Index Std | 21300 | 0.03% | -- | -- | 2018-03-31 |
| AXA 2000 Managed Volatility K | 116872 | 0.13% | -- | -- | 2018-05-31 |
| ATM Small Cap Managed Volatility K | 23291 | 0.03% | -- | -- | 2018-05-31 |
| AXA/Lord Abbett Micro Cap K | 14505 | 0.02% | -- | -- | 2018-05-31 |
| Voya Russell Small Cap Index Port I | 29165 | 0.04% | 12209 | 72.00% | 2018-03-31 |
| BNY Mellon EB DL Small Cap SIF | 57762 | 0.07% | 41894 | 264.02% | 2018-03-31 |
| Master Small Cap Index | 52290 | 0.06% | -- | -- | 2018-05-31 |
| Vanguard Russell 2000 ETF | 85562 | 0.10% | 1331 | 1.58% | 2018-05-31 |
| Schwab Small Cap Index | 168200 | 0.19% | -- | -- | 2018-05-31 |
| Northern Trust Russell 2000 Index Fund - DC - Non-Lending | 174688 | 0.20% | 1277 | 0.74% | 2018-05-31 |
| Northern Small Cap Index | 42536 | 0.05% | 25538 | 150.24% | 2018-03-31 |
| BlackRock Russell 2500 | 40109 | 0.05% | 33179 | 478.77% | 2018-03-31 |
| BlackRock Russell 2000 | 127957 | 0.15% | 86389 | 207.83% | 2018-03-31 |
| iShares Russell 2000 Growth | 684380 | 0.84% | 1180 | 0.17% | 2018-06-21 |
| Kenneth M. Bate | Kenneth M. Bate is a businessperson who founded JSB-Partners LP and who has been the head of 6 different companies. Presently, he is Chairman for Catabasis Pharmaceuticals, Inc. and Chairman for Genocea Biosciences, Inc. Mr. Bate is also on the board of AVEO Pharmaceuticals, Inc., Epizyme, Inc. and Madrigal Pharmaceuticals, Inc. In his past career Kenneth M. Bate occupied the position of Chief Executive Officer of Mpm Capital LLC, Chief Financial Officer at Biogen, Inc. and Chief Financial Officer, VP-Sales & Marketing at Biogen MA, Inc. (a subsidiary of Biogen, Inc.), Partner at JSB-Partners LP, Lead Independent Director at Cubist Pharmaceuticals LLC, President, Chief Executive Officer & Director at Archemix Corp., President, Chief Executive Officer & Director at NitroMed, Inc. and CFO & Head-Commercial Operations at Takeda Oncology Co. Kenneth M. Bate received an undergraduate degree from Williams College and an MBA from The Wharton School of the University of Pennsylvania. |
|---|---|
| Michael John Higgins | Michael John Higgins is Chairman for Voyager Therapeutics, Inc. Mr. Higgins is also on the board of 5 other companies. In his past career he occupied the position of Chief Operating Officer of Ironwood Pharmaceuticals, Inc., Chief Financial Officer of Boston Business Journal, Group Vice President at Jacobs Engineering Group, Inc. and Director & Vice President at Jacobs One Ltd. (a subsidiary of Jacobs Engineering Group, Inc.), Vice President-Finance & Business Development at Genzyme Corp. and Chief Financial Officer for Procept, Inc. Michael John Higgins received an undergraduate degree from Cornell University, an MBA from Tuck School of Business at Dartmouth and a graduate degree from Dartmouth College. |
| Thomas Andrew Davis | Currently, Thomas Andrew Davis holds the position of Chief Medical Officer for Genocea Biosciences, Inc. In the past Dr. Davis occupied the position of Chief Medical Officer & Executive Vice President at Celldex Therapeutics, Inc. and Chief Medical Officer & Senior Vice President of AVANT Immunotherapeutics, Inc. (a subsidiary of Celldex Therapeutics, Inc.), Chief Medical Officer & VP-Clinical Development at Celldex Research Corp., Chief Medical Officer of Gadeta BV, Chief Medical Officer of GenVec, Inc. and Senior Director-Clinical Science at Medarex, Inc. He received a doctorate and a graduate degree from Georgetown University and an undergraduate degree from The Johns Hopkins University. |
| William D. Clark | William D. Clark founded Vanda Pharmaceuticals, Inc. Presently, he is President, Chief Executive Officer & Director at Genocea Biosciences, Inc. In the past Mr. Clark held the position of Principal at Care Capital LLC and Secretary, Chief Business Officer & Senior VP at Vanda Pharmaceuticals, Inc. He received an undergraduate degree from Harvard University and an MBA from The Wharton School of the University of Pennsylvania. |
| Michael John Higgins | Michael John Higgins is Chairman for Voyager Therapeutics, Inc. Mr. Higgins is also on the board of 5 other companies. In his past career he occupied the position of Chief Operating Officer of Ironwood Pharmaceuticals, Inc., Chief Financial Officer of Boston Business Journal, Group Vice President at Jacobs Engineering Group, Inc. and Director & Vice President at Jacobs One Ltd. (a subsidiary of Jacobs Engineering Group, Inc.), Vice President-Finance & Business Development at Genzyme Corp. and Chief Financial Officer for Procept, Inc. Michael John Higgins received an undergraduate degree from Cornell University, an MBA from Tuck School of Business at Dartmouth and a graduate degree from Dartmouth College. |
| William D. Clark | Dr. Seth V. Hetherington, MD, is Chief Medical Officer at Genocea Biosciences, Inc. Dr. Hetherington was previously employed as SVP-Clinical & Regulatory Affairs by Neusentis, Inc., Chief Medical Officer & VP-Clinical Development by Inhibitex, Inc., Head-Clinical Program by GlaxoSmithKline, Inc., Head-Clinical Program by Glaxo Wellcome, Inc., and a Principal by University of North Carolina at Chapel Hill. He received his undergraduate degree from Yale University and a doctorate degree from the University of North Carolina at Chapel Hill. |
| Katrine S. Bosley | Katrine S. Bosley is on the board of Galapagos NV, Biotechnology Innovation Organization, Genocea Biosciences, Inc. (former Chairman) and Massachusetts Eye & Ear Infirmary, Inc. In the past she was President & Chief Executive Officer of Editas Medicine, Inc., Director-Decision Support at Biogen, Inc., Chief Executive Officer of Avila Therapeutics, Inc., Vice President-Strategic Operations at Adnexus, President-Celgene Avilomics Research at Celgene LLC and Principal at Alkermes, Inc. She received an undergraduate degree from Cornell University. |
| Kenneth M. Bate | Kenneth M. Bate is a businessperson who founded JSB-Partners LP and who has been the head of 6 different companies. Presently, he is Chairman for Catabasis Pharmaceuticals, Inc. and Chairman for Genocea Biosciences, Inc. Mr. Bate is also on the board of AVEO Pharmaceuticals, Inc., Epizyme, Inc. and Madrigal Pharmaceuticals, Inc. In his past career Kenneth M. Bate occupied the position of Chief Executive Officer of Mpm Capital LLC, Chief Financial Officer at Biogen, Inc. and Chief Financial Officer, VP-Sales & Marketing at Biogen MA, Inc. (a subsidiary of Biogen, Inc.), Partner at JSB-Partners LP, Lead Independent Director at Cubist Pharmaceuticals LLC, President, Chief Executive Officer & Director at Archemix Corp., President, Chief Executive Officer & Director at NitroMed, Inc. and CFO & Head-Commercial Operations at Takeda Oncology Co. Kenneth M. Bate received an undergraduate degree from Williams College and an MBA from The Wharton School of the University of Pennsylvania. |
| Katrine S. Bosley | Ms. Katrine S. Bosley is a President, Chief Executive Officer & Director at Editas Medicine, Inc., a Chairman at Genocea Biosciences, Inc. and an Independent Non-Executive Director at Galapagos NV. She is on the Board of Directors at Editas Medicine, Inc., Galapagos NV and Biotechnology Innovation Organization. Ms. Bosley was previously employed as a President-Celgene Avilomics Research by Celgene LLC, a President & Chief Executive Officer by Avila Therapeutics, Inc., a Vice President-Business Development by Adnexus A Bristol-Myers Squibb R&D Co., a Principal by Alkermes, Inc., and a Director-Decision Support by Biogen, Inc. She also served on the board at CoCo Therapeutics Ltd. and Scholar Rock, Inc. She received her undergraduate degree from Cornell University. |
| George R. Siber | George R. Siber holds the position of Chief Scientific Officer at Clearpath Vaccines Co. He is also on the board of Genocea Biosciences, Inc. (former Executive Chairman) and International Vaccine Institute. In the past Dr. Siber held the position of Chief Scientific Officer & Executive VP at Wyeth Corp., Associate Professor at Dana-Farber Cancer Institute, Inc. and Associate Professor at Harvard Medical School. George R. Siber received a doctorate from McGill University and an undergraduate degree from Bishop's University. |
| Ali Behbahani | Currently, Ali Behbahani occupies the position of General Partner for NEA Management Co. LLC. Dr. Behbahani is also Partner at New Enterprise Associates LLC and on the board of 13 other companies. In the past he was Consultant at The Medicines Co., Analyst at Lehman Brothers Asset Management LLC and Venture Associate at Morgan Stanley Venture Partners. Dr. Behbahani received an undergraduate degree from Duke University, an MBA from The Wharton School of the University of Pennsylvania and a doctorate from Perelman School of Medicine. |
| Jennifer LaVin | Currently, Jennifer LaVin is Press Contact at Genocea Biosciences, Inc. Ms. LaVin previously occupied the position of Director-Investor Relations of Cubist Pharmaceuticals, Inc. |
| Jessica Baker Flechtner | Currently, Jessica Baker Flechtner is Chief Scientific Officer of Genocea Biosciences, Inc. She is also Member of International Society for Biological Therapy of Cancer, Member of The American Association of Immunologists, Member of American Society for Microbiology, Member of Women in Bio, Inc., Member of President's Council of Cornell Women and Member of American Association for Cancer Research. In her past career Dr. Flechtner occupied the position of Principal at Mojave Therapeutics, Inc. Dr. Flechtner received an undergraduate degree and a doctorate from Cornell University. |
| Howard Mayer | Dr. Howard Mayer, MD, is an Independent Director at Genocea Biosciences, Inc. and a Chief Medical Officer, Senior VP, Head-R&D at Shire Plc. He is on the Board of Directors at Entasis Therapeutics Holdings, Inc., Genocea Biosciences, Inc. and Melmark Charitable Foundation. Dr. Mayer was previously employed as a Chief Medical Officer by EMD Serono, Inc. and a Head-Clinical Development & Medical Affairs by Pfizer Inc. He also served on the board at Autism Speaks, Inc. He received his undergraduate degree from the University of Pennsylvania and a doctorate degree from Albert Einstein College of Medicine, Inc.. |
| Pamela Carroll | Pamela Carroll is Senior Vice President-Immuno-Oncology at Genocea Biosciences, Inc. In her past career she was Vice President-Oncology Scientific Innovation at Janssen Pharmaceuticals, Inc. and Head-Nutley Oncology Discovery Site at Roche Pharmaceuticals, Inc. Pamela Carroll received an undergraduate degree from St. Michael's College and a doctorate from Stony Brook University. |
| Ronald H. W. Cooper | Presently, Ronald H. W. Cooper holds the position of President, Chief Executive Officer & Director at Albireo Pharma, Inc. and President, Chief Executive Officer & Director at Albireo AB (a subsidiary of Albireo Pharma, Inc.). He is also on the board of Genocea Biosciences, Inc. and Albireo Ltd. (former President, Chief Executive Officer & Director). In the past he was President-Europe at Bristol-Myers Squibb Co. He received an undergraduate degree from St. Francis Xavier University. |
| Diantha Duvall | Diantha Duvall occupies the position of Chief Financial Officer of Genocea Biosciences, Inc. In the past Ms. Duvall occupied the position of Global Commercial Controller at Biogen, Inc. and Chief Accounting Officer, VP & Controller at Bioverativ, Inc. Ms. Duvall received an MBA from Northeastern University and a graduate degree from Colby College. |
| Narinder Singh | Narinder Singh is Senior VP-Pharmaceutical Sciences & Manufacturing at Genocea Biosciences, Inc. and VP-Drug Product Development & Manufacturing at Momenta Pharmaceuticals, Inc. He received an undergraduate degree and a graduate degree from Indian Institute of Technology New Delhi, a graduate degree from the University of Houston and an MBA from UCLA Anderson School of Management. |
| Michael Alfieri | Michael Alfieri is Chief Accounting Officer of Genocea Biosciences, Inc. In his past career Mr. Alfieri occupied the position of Vice President-Finance of Radius Health, Inc., Controller at Merrimack Pharmaceuticals, Inc. and Controller & Executive Director-Finance at Anika Therapeutics, Inc. He received an undergraduate degree and a graduate degree from Bentley University. |
| Derek M. Meisner | Currently, Derek M. Meisner holds the position of Senior Vice President & General Counsel of Genocea Biosciences, Inc. In his past career Mr. Meisner occupied the position of Partner at K&L Gates LLP and General Counsel for Quantopian, Inc. He received an undergraduate degree from the University of Michigan and a graduate degree from American University Washington College of Law. |
| Girish Aakalu | Girish Aakalu is Chief Business Officer at Genocea Biosciences, Inc. He received an undergraduate degree from The Johns Hopkins University and a doctorate from California Institute of Technology. |
| Sudhir Rao | Sudhir Rao is Senior Director-Business Development at Genocea Biosciences, Inc. |
| Sudhir Rao | Sudhir Rao is Senior Director-Business Development at Genocea Biosciences, Inc. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论